- Datum22.12.2025
- Uhrzeit17:00 - 19:00 Uhr
- Veranstalter
stock3
Cordula Lucas
Moderator
Abeona Therapeutics Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Abeona Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
3,87 %
Intraday
-4,76 %
1 Woche
21,55 %
1 Monat
-8,35 %
Seit Jahresbeginn
-9,33 %
1 Jahr
100,98 %
3 Jahre
-86,74 %
5 Jahre
-94,22 %
10 Jahre
Passender Service zu Abeona Therapeutics Inc.
Webinar zu Abeona Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,933-7,540
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Abeona Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Abeona Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
